Sidki A M, Smith D S, Landon J
Ther Drug Monit. 1985;7(1):101-7. doi: 10.1097/00007691-198503000-00018.
A dual-label magnetizable solid-phase fluoroimmunoassay for direct determination of serum levels of primidone and its main metabolite, phenobarbital, in a single tube was developed and optimized. Fluorescein isothiocyanate was used to label phenobarbital and a rhodamine 101 derivative (XRITC) to label primidone; these could be independently quantitated with no fluorimetric "cross-talk." The dual-label assay employs mixed immunochemical reagents but is otherwise similar in performance to conventional, single-drug, magnetizable solid-phase fluoroimmunoassays. The ability to measure simultaneously two related analytes, such as a drug and its metabolite, represents a useful extension of immunoassay. This was illustrated in the present work by assay of sera from patients on primidone therapy. Dual-label assay results correlated well with those by a conventional enzymoimmunoassay (for primidone) and by a polarization fluoroimmunoassay (for phenobarbital).
开发并优化了一种双标记可磁化固相荧光免疫分析法，用于在单管中直接测定血清中扑米酮及其主要代谢物苯巴比妥的水平。用异硫氰酸荧光素标记苯巴比妥，用罗丹明101衍生物（XRITC）标记扑米酮；它们可以独立定量，不存在荧光“串扰”。双标记分析法采用混合免疫化学试剂，但其性能在其他方面与传统的单药可磁化固相荧光免疫分析法相似。同时测量两种相关分析物（如药物及其代谢物）的能力代表了免疫分析的有益扩展。本研究通过对接受扑米酮治疗患者的血清检测对此进行了说明。双标记分析法的结果与传统酶免疫分析法（用于扑米酮）和偏振荧光免疫分析法（用于苯巴比妥）的结果相关性良好。
